- Lexaria
Bioscience continues to advance the effectiveness of its proprietary
DehydraTECH technology, a formulation that teams with drug substances such
as nicotine and cannabidiol to quickly carry those drugs into a user’s
blood stream
- Recent
concerns about the safety of vape products and ongoing concerns about the
safety of tobacco are opening doors to Lexaria’s edible technology
- Newly
legalized cannabis-infused edibles began hitting store shelves nationwide
in Canada last month, presenting Lexaria with new potential licensing
outlets for its increasingly effective products
If 2019 was the year when vape users discovered the
potential perils of using untested off-brand products, 2020 may well be the
year when vape users share the common woe of struggling to beat an addiction.
The U.S. Centers for Disease Control and Prevention (CDC)
reported at year’s end that 2,561 people had been hospitalized with the
vape-related lung illness now known as ‘e-cigarette or vaping product
use-associated lung injury’ (EVALI) as of December 27, that the illness had
afflicted every U.S. state and two territories, and that 55 EVALI-related
deaths had been confirmed in 27 states and the District of Columbia, with the
incidence of new cases in decline (http://ibn.fm/mh8Ga).
With the advent of the new year, anti-youth vaping advocacy
group Truth Initiative reported (http://ibn.fm/ZmCUn) a survey that showed “nearly half of
young people are looking to quit vaping as their New Year’s resolution.” Many
parents find themselves fighting back fears of the potential outcomes as they
see their children drawn into addictive behaviors (http://ibn.fm/XooYb).
Oral drug product innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a
company dedicated to the concept that there are better alternative methods for
drug substance use than inhalation. The British Columbia-based bio-delivery
technology developer patented its DehydraTECH™ oral drug delivery technology
and has been continuing to advance its ability to pair the IP with substances
such as nicotine and cannabidiol (CBD) for access to users’ bloodstreams at
rapid rates comparable to the speed of acquisition by inhalation.
Swallowed medications have historically been slower to
provide effective action than inhaled ones, leading substance users looking for
a quick fix to lean toward the latter. But the deleterious and deadly
consequences of smoking tobacco products have been publicly acknowledged for
decades, though hardly stemming the tide of nicotine addiction as one
generation succeeds another.
The continued preference for the rapid delivery of inhaled
drug substances has led many researchers to seek alternatives beyond deterrence
campaigns. DehydraTECH’s newest formulation was recently shown to deliver to
deliver 811 percent more CBD into the bloodstream than generic industry control
formulations, nearly doubling the capacity of existing DehydraTECH technology.
It was additionally shown to deliver 1,937 percent more CBD across the
blood-brain barrier into brain tissue than generic industry control formulations
and 487 percent more than the original DehydraTECH technology (http://ibn.fm/YEn9J).
The blood-brain barrier is a natural biological system of
blood vessels and endothelial cells that bar nearly all small-molecule drugs
from accessing the brain’s central nervous system hierarchy and finding the
ability to defeat it has been a primary concern for medical product developers.
The potential applications of Lexaria’s technology are many.
Perhaps most noticeable at the moment is the uses arising from the legalization
of cannabis-infused food on a national basis in Canada, with the first products
in store shelves as of last month (http://ibn.fm/k0GHu), but the technology also creates the
potential for vape makers to offer non-inhaled products to shore up their
marketing.
The company has begun licensing its technology to a variety
of other producers in the cannabis and tobacco spaces. Lexaria’s licensed
in-house research laboratory and its IP portfolio have developed 16 patents
with over 60 patents pending worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
